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Cereblon (CRBN), target of immunomodulatory drugs (IMiDs), forms the CRL4CRBN E3 
ubiquitin ligase (CRL4) complex with DDB1, CUL4B and ROC1.1,2 Under the influence of 
IMiDs, CRL4 polyubiquitinates and thus depletes the transcription factors IKZF1 and IKZF3, 
resulting in cytotoxicity to multiple myeloma (MM) cells. In vitro, CRBN and IKZF1/3 
mutations affecting the CRBN-Lenalidomide (LEN) binding site (degron) cause drug 
resistance to IMiDs.3–5 Here, we hypothesized that mutations in the other components of the 
CRL4 complex and its targets Ikaros and Aiolos likewise interfere with the ubiquitin ligase 
activity, thus contribute to IMiD resistance. In order to select the most promising patient 
derived mutation candidates for functional validation, we first generated a comprehensive 
overview of point mutations in advanced MM patients affecting IKZF1, IKZF3 or CRL4 genes. 
Next, we contextualized all described mutations at the protein level, to investigate their 
structural impact on complex formation and stability. Based on these analyses, we then 
selected a subset for functional validation by expressing mutant IKZF1, CRBN or CUL4B in 
MM cell lines and analyzed their effects on resistance to IMiDs, thus probing the relevance of 
such alterations for complex integrity and the transmission of IMiD activity. 
To select relevant mutation candidates, we analyzed data from different Multiple Myeloma 
Mutation panel (M3P) cohorts3,6–8 and from other published and unpublished datasets9,10 for 
a total of 1,838 MM cases (Supplemental methods). In this meta-analysis we observed the 
mutation frequency increased significantly after treatment (Z-score: 4.5, p<0.00001), from 
2.0% (28/1373) in untreated to 6.2% (29/465) in pretreated cases. Notably, this increase 
occurs predominantly in three genes, IKZF1 (0.15% to 1.3%, Z-score: 2.9, p=0.001), CRBN 
(0.44% to 2.15%, Z-score: 3.4, p=0.006) and CUL4B (0.44% to 1.93%, Z-score: 3.4, 
p=0.004, Supplemental figure 1). 71% (24/34) of the IKZF1/3, CRBN, DDB1, CUL4B and 
ROC1 mutations found in treated patients were nonsense or located within previously 
described binding areas, whereas at diagnosis the distribution was spread out all along the 
gene loci2,4,11  suggesting passenger mutations. We identified three potential new hotspots 
(IKZF3 G159R/A, IKZF1 A152T and CUL4B R820T/S) each represented by mutations in two 
different patients. All the detected mutations and variant read frequencies (VRF) are 
summarized in Supplemental table 1. Of interest, in eight patients with sampling available 
from diagnosis and relapse, CRBN and CUL4B mutations were acquired after IMiD 
treatment, whereas IKZF3 mutations were also identified in de novo disease (Supplemental 
figure 1). Together, these results suggest that CRL4 mutations play an important role in 
disease progression and clonal evolution.  
Next, we functionally assessed effects of patient-derived mutations in Ikaros and Aiolos. We 
constructed Sleeping Beauty vectors for expression of four IKZF1 mutations (A152T, E170D, 
Y413C and R439H), and for one in IKZF3 (G159R) (Figure 1A), and stably introduced these 
into MM cell lines (MM1.S and L363: IMiD sensitive, AMO1: less sensitive). Whereas this led 
to strong expression for all IKZF1 constructs, the IKZF3 expression vectors (WT and 
G159R), unfortunately, did not lead to noticeable expression even though two different 
versions using either CMV- or CAAG-driven expression cassettes, were tested 
(Supplemental figure 2). Viability assessments for all L363 IKZF1 sub-lines after six-day-
treatment with 10 µM LEN showed that exclusively the mutation at the LEN binding site 
(A152T) conferred resistance to the drug (Figure 1B, top). This observation was supported 
by Western blotting, which showed that only in A152T subline overnight treatment with LEN 
was without effect on the level of Ikaros (Figure 1B, bottom). Furthermore, a minor inhibitory 
effect on IKZF1 degradation was also observed for the mutation E170D, which is located 
within close proximity of the degron sequence. This result was confirmed in cell lines AMO-1 
(Supplemental figure 2B) and MM1.S (not shown). However, the slightly enhanced levels of 
IKZF-E170D after LEN treatment did not lead to measurable changes in cell viability and 
apoptosis assays. In order to investigate the biological effects of IKZF1-E170D on 
proliferation fitness under Len treatment, we employed a clonal competition assay (CCA) and 
tested L363 co-cultures of fluorescently-identifiable sublines (IKZF1-WT vs IKZF-A152T, 
IKZF-E170D or IKZF-R439H) growing under the selective pressure of a modest 
concentration of LEN (2,5 µM, Supplemental methods). Of note, IKZF1-A152T cells had a 
significant survival advantage compared to IKZF1-WT cells. Complete dominance in the 
culture (inversion from an initial ratio of 10% mut/90% WT to 90% mut/10 % WT) was 
observed after 21 days in co-culture. No such effect was observed for IKZF-E170D and 
IKZF-R439H cells (Figure 1C), which is in line with published data, that exclusively 
mutations affecting the IKZF1 degron sequence4 induce IMiD resistance. 
We previously demonstrated that loss of CRBN or the occurrence of mutations at the IMiD 
binding site of CRBN induce resistance to immunomodulatory drugs.3 However, 56% of the 
missense CRBN mutations did not affect the IMiD binding pocket, but were present in the 
previously described CRBN Lon-like domain (LLD; residues 76-318), that contains a DDB1-
binding motif (Figure 2A).11 Furthermore, in silico analysis12 suggests that 7 of 9 mutations 
affect this region  (P85S, R111Q, F120V, D291N, L308F, R309H and I314S), thus may lead 
to a reduction of CRBN stability (predicted stability change ∆∆G<0, Supplemental table 1). 
To understand whether these alterations also affect IMID sensitivity, we selected two CRBN 
mutations detected in IMID resistant patients (R309H and L190F) and lentivirally introduced 
them into OCIMY5 cells (cells that have very low levels of endogenous CRBN expression 
and, thus are resistant to IMiDs). As shown in Figure 2B, both types of CRBN mutant-
transduced cells showed a substantial reduction of sensitivity to LEN compared with WT 
CRBN transduced cells. However, further immunoblotting indicated that exogenous CRBN 
expression in the mutant-transfected cells was much lower than in WT CRBN transduced 
cells. In order to analyze whether this effect was related to intrinsic features of the mutations, 
we performed a titration of WT CRBN virus (1000 virus equivalents to 75) and found that a 
decrease of virus equivalents correlates with decreases in RNA and protein levels of CRBN 
in the infected MM cells. Although both CRBN mutant virus preparations show the highest 
virus equivalents, and although this corresponds to high levels of expressed CRBN RNA in 
OCIMY5 cells, these cells fail to express equivalent levels of CRBN protein (Figure 2C). 
These results suggest that in addition to CRBN mutations in the IMiD binding site other point 
mutations may play a role in IMiD resistance development either through impaired binding 
with other proteins of the complex or through destabilizing effects on the protein.  
We also hypothesized that mutations in DDB1, CUL4B and ROC1 may affect the formation 
of the CRL4 complex (Figure 3A). To confirm this, we prepared a CUL4B KO model (in L363 
cells) using the CRISPR/Cas9 system. Of 10 viable clones, we selected one with clear KO of 
CUL4B (Figure 3B, top). The KO clone was more resistant to LEN treatment compared to 
the naïve L363 cells. This effect was confirmed by clonal competition assay, in which an 
advantage in survival fitness under the selective pressure of Len was observed for the 
CUL4B KO clone compared to the CUL4B WT cells (Figure 3B, bottom left). The clonal 
dynamics become even clearer when both CUL4B KO and WT cells are initially present in 
equal amounts and cultured without LEN. The wildtype cells easily outcompete the CUL4B 
KO clone under these conditions, but once the drug is added (2,5 µM, at day 21 in co-
culture) the resistant clone takes over (Figure 3B, bottom right). Of note, the re-introduction 
of WT CUL4B into the CUL4B knockout cells re-sensitized the cells to LEN, confirming our 
hypothesis. Likewise, reintroduction of two other CUL4B mutants from IMiD pretreated 
patients (D311H, and R820S, a hotspot mutation detected in two MM patients) also reverted 
the resistance, suggesting that these two mutations do not alter the response to IMiDs 
(Supplemental figure 3).  
We confirmed an increase of mutations in CRBN3 and detected similar results for CUL4B and 
IKZF1 after therapy. In eight cases of our cohort with acquired mutations within the CRL4 
complex, a prior tumor sample was available (diagnosis-progression/relapse). In these 
sequential samples CRBN and CUL4B mutations were acquired after IMiD exposition, in 
contrast, alterations in IKZF3 were already detectable at diagnosis. This suggests that IKZF3 
mutations might play a role in the pathogenesis of MM rather than in therapy-induced 
resistance development. Recently, CRBN protein loss and point mutations in the CRBN-LEN 
binding area were associated with IMiD resistance.3 Mutations in the CRBN-DDB1 binding 
motif11 may also induce resistance to LEN (Figure 2B). However, the underlying 
mechanisms of the mutations investigated were not related to binding, but may lead to the 
destabilization of the protein folding that induces CRBN degradation (Figure 2C). The KO by 
CRISPR/Cas9 of CUL4B induced resistance to LEN, highlighting the importance of this 
protein for the anti-tumor action of IMiDs. The fact that this resistance was overcome by the 
reintroduction of CUL4B WT using Sleeping Beauty proved the specificity of our in vitro 
approach (Figure 3B).  
This is the first comprehensive analysis of CRL4 point mutations on the impact of IMiD 
responses in MM. Mutations are predominantly selected for by therapy and affect the 
function of the ubiquitin ligase complex through loss of a subunit by nonsense mutation, point 
mutations affecting protein stability, or by impairment of substrate binding. Some alterations, 
including IKZF3 hotspot mutations, are detectable prior to treatment at initial diagnosis. The 
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Figure legends  
Figure 1: Only IKZF1/3 mutations affecting the LEN/CRBN binding area induce LEN 
resistance. A: Location of the mutations within the IKZF3 and IKZF1 genes. Lollypop plots 
of all mutations described in IKZF1 and IKZF3. Blue bar; degron sequence of the LEN 
binding site. Bottom of the lollypop plot: mutations detected at diagnosis. Top: alterations 
detected after therapy exposition. Green dots indicate missense and black dots nonsense 
mutations. B: Viability and molecular effects of expression of mutated IKZF1 in L363 cells. C: 
Clonal competition assay (CCA) results for IKZF1-WT (red) vs IKZF-A152T, IKZF-E170D or 
IKZF1-R439H (green). Dashed line: CAA without drug (10% mutant/90% WT). Solid line: 
CCA with 2.5 µM LEN. 
Figure 2: CRBN point mutations outside the LEN binding pocket induce protein 
destabilization. A: CRBN mutations at diagnosis and progression. B: Viability test analyses 
(MTT) after 5 day incubation with 5 µM LEN and Western blotting for the different CRBN 
constructs C: Virus titration of the CRBN constructs, compared to RNA expression level 
(TaqMan assays) and protein quantity (Image). 
Figure 3: Loss of CUL4B induces LEN resistance in vitro. A: DDB1, CUL4B and ROC1 
mutations in myeloma patients. B: Top left: Western blotting of CUL4B WT and KO before 
and after the introduction of the CUL4B WT or mutant by transfection. Top right: Sequence of 
the CUL4B KO clone compared to WT. Bottom left: Clonal competition assay (CCA) results 
for CUL4B KO transformed with CUL4B WT (red) vs CUL4B KO (green). Dashed line: 
Untreated cells. Solid line: CCA with 2.5 µM LEN. Bottom right: CCA of the same subline 
combinations without LEN (days 0-21) and after subsequent LEN addition (day 21-40) 







The meta-analysis was restricted to cohorts that include progression samples. Informed consent was 
obtained according to the declaration of Helsinki in all patients. We pooled 1,373 newly diagnosed 
MM (NDMM) cases including: Group_1D: 890 cases with WES data available at baseline (CoMMpass 
IA12 release).
23
 Group_2D: own 331 M3P newly diagnosed cases. Group_3D: 152 untreated cases from 
previously published datasets (WES).
21,22
 We compared the incidence in these NDMM groups with 
progression samples after therapy (465 cases): Group_1R: 148 WES data from confirmed last relapses 
in CoMMpass IA12. Group_2R: 164 M3P pretreated cases.
11,18–20
, and Group_3R: 115 pretreated cases 
from previously published datasets.
21,22
 Group_4R: 38 WGS advanced, multi-refractory MM cases 
obtained from a collaboration with the University of Heidelberg (unpublished data). 
Targeted deep sequencing 
Targeted deep sequencing was performed on paired tumor-germline DNA-samples using the Ion 
Torrent platform (PGM, Thermo Fisher) and Ion AmpliSeq Library kit. The M3P panel includes in its 
last version 1,327 amplicons covering the coding regions of 88 myeloma-relevant genes.
24
 An average 
of 759× depth sequencing coverage was generated per nucleotide. Mutation analysis annotation and 




Whole genome sequencing 
WGS was performed on MACS sorted CD138+ tumor cells and germline controls. Preparation of DNA 
libraries was done using the TruSeq DNA Nano kit, sequencing was performed on the HiSeq X using 
the HiSeq X Ten Reagent kit v2.5 (all Illumina, Hayward, CA) obtaining a median coverage of 77x. 
Alignment workflow consisted of mapping of raw reads to the human reference genome build 37, 
version hs37d5, using BWA mem v0.7.8, sorting using SAMtools v0.1.19, and marking of duplicate 
reads using Sambamba v0.5.9. Somatic SNVs and small indel calling was performed using Mpileup 
v0.1.19 and Platypus v0.8.1, respectively, and high confidence variants were defined. 
Structural analysis 
The structural analysis was performed with Chimera 1.11 software
26
 and data from public databases 
(Protein Data Bank). The complete structure of CRL4-CRBN E3 ubiquitin ligase was obtained by 
merging the structures of LEN-CRBN-DDB1 (PDB_4TZ4) and DDB1-CUL4B-ROC1 (PDB_4A0L), using 
DDB1 as common polypeptide domain.
7,27
 In silico prediction of protein stability induced by mutations 
was performed with the Site Directed Mutator tool.
28
 
Site-directed mutagenesis for functional CRBN mutation analysis 
To establish mutant CRBN-expressing OCI-MY5 cell lines, we created lentivector pCDHPuroCRBN by 
subcloning wild-type (WT) CRBN from pCDHGFPCRBN and used this pCDHPuroCRBN as a template to 
introduce CRBN mutations by PCR as we previously described.11 The ligated plasmid was amplified and 
isolated by using a Miniprep Plasmid Isolating Kit (QIAGEN) and then cloned into lentivector pCDH-
CMV-MCS-EF1-Puro (SBI, Mountain View, CA) and packaged into a lentivirus. The lentivirus expressing 
WT-CRBN and mutant-CRBN were then used to infect OCI-MY5 myeloma cells to overexpress both WT 
and mutant CRBN protein. The infected cells were selected with Puromycin for two weeks. The cell 
viability was assessed in triplicate by using 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium 
bromide (MTT) after a 5-day incubation time with different concentrations of LEN.   
CUL4B knock out and mutated CUL4B reintroduction 
Oligonucleotides for targeting Exon 3 of CUL4B gene with the help of CRISPR-Cas9 were designed and 
cloned into a GeneArt CRISPR nuclease vector (A21175, Thermo Fisher Scientific). L363 cells were co-
electroporated with this vector and an expression vector for EGFP, and purified via CD4-microbead 
selection. Subsequently, undamaged bright green cells were manually picked and seeded into a 96-
well plate for clonal upgrowth. Clones were screened for CUL4B status by Western blotting. The exact 
type of genomic alteration introduced by CRISPR-Cas9 was determined by Sanger sequencing and the 
complete knockout (KO) of CUL4B protein was verified by Western blotting as described before.
29
 
CUL4B-WT and CUL4B-mutant (D311H and R820S) protein was then expressed in these KO cells by 
transposition with Sleeping Beauty (SB) vectors coding for the respective genes. Polyclonal cultures of 
stable transformants were established by puromycin selection for about 2 weeks and then used in 
functional experiments such as viability (alamarBlue) and apoptosis assays (annexin 
V/propidiumiodide)
30
, and for Western blotting. For functional experiments in 96-well format 1500 
cells per well of either L363 CUL4B-KO, CUL4B-WT or CUL4B-mutant cells were seeded and treated 
with 10 µM LEN for 6 days. 
Clonal competition assays 
To characterize the induction of cell resistance over time by the selected mutations in isogenic cells, 
we established a clonal competition assay system (CCA) using again a SB approach but with G418 
selection to stably transfect L363 cells with EGFP and/or LSS mKate RFP. Briefly, after establishment 
of stably transfected polyclonal cultures of CUL4B mutant / WT marked with different fluorescence 
proteins, we mixed 90% of “reference-EGFP” cells with 10% of the “mutant-RFP” sub-line and co-
cultured them for 40-60 days in the presence or absence of LEN. All experiments were conducted in 
triplicate to rule out that the observed effects were the result of coincidental alterations acquired over 
the long culture period. In addition, reference/mutant EGFP/RFP fluorescence was switched in one of 
the replicates to confirm that the effects are not related to the presence of any specific fluorescent 
protein. The ratio of EGFP and RFP cells was determined every 4-10 days by flow cytometry, and 
Sanger sequencing confirmed the genetic integrity of the mutants at the end of the experiment. 
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